|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.41 - 0.43|
|52 Week Range||0.15 - 0.89|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OTC:ZENO Zenosense, Inc. (OTC:ZENO) is a healthcare technology company located in Valencia, Spain. The company’s main focus is a novel hand-held point-of-care (POC) cardiac diagnostic device called MIDS ...
Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held device for the early detection of heart attack at the Point of Care, is pleased to announce that the Company is now trading on the OTC Markets Group OTCQB “Venture Market”. The OTCQB is recognized as an Established Public Market by the U.S. Securities and Exchange Commission and is a leading market for entrepreneurial and development stage U.S. and international companies.
New York, New York--(Newsfile Corp. - June 28, 2018) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Diagnostics Play Critical Role in Medical Sector," featuring Zenosense (OTC Pink: ZENO). To hear the NetworkNewsAudio version, visit http://nnw.fm/kqyU7To read the original editorial, visit http://nnw.fm/8ZAlrDeveloped by the Company's MIDS Medical Limited joint venture (MML) based at the prestigious Sci-Tech Daresbury campus in the United Kingdom, MIDS Cardiac is a handheld POC technology for the detection of ...
NEW YORK, June 27, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Zenosense (ZENO), a client of NNW and healthcare technology developer focused on transformational, disruptive medical diagnostic projects. The introduction of accurate handheld devices such as MIDS Cardiac is an important step for the POC market. Many of the most effective detection systems are too large and unwieldy to be used at the POC.
Zenosense, Inc. (OTC PINK: ZENO) ("Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce that its MIDS Medical Ltd. joint venture ("MML") has successfully completed a second testing round of its revised detection system. In 2017 the first next generation troponin assay for the early diagnosis of heart attack was approved for use in the U.S. by the FDA.
Zenosense, Inc. (OTC PINK: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care handheld device for the early detection of certain cardiac event biomarkers. We believe that MIDS Cardiac will significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain symptomatic of acute myocardial infarction (heart attack). The MIDS Cardiac development is being carried out by our MIDS Medical Limited joint venture ("MML") based at Sci-Tech, Daresbury (UK). The Company notes the recent decline in its share price and knows of no operational reason for this. The development by MML of the MIDS technology platform is progressing as planned.
Zenosense, Inc. , a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care handheld device for the early detection of certain cardiac ...